Endologix (ELGX) Tops Q3 EPS by 1c

Go back to Endologix (ELGX) Tops Q3 EPS by 1c

Endologix Reports Third Quarter 2015 Financial Results

October 26, 2015 4:03 PM EDT

Nellix European Systems Increase 45% Over Prior Year

FDA Approves Additional Patient Enrollment in Nellix U.S. CAP

IRVINE, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2015.

John McDermott, Endologix Chairman and Chief Executive Officer, said, "We achieved solid third quarter results, highlighted by a 45% increase in European Nellix® system sales. We are also pleased with FDA... More

Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders

October 26, 2015 4:02 PM EDT

Combined Product Portfolio to Provide Clinicians With a Broad Range of Endovascular AAA Devices

Will Expand U.S. and European Sales Organizations to Enhance Growth and Provide Excellent Clinical Support

Endologix to Host Conference Call Today at 5:00 p.m. ET

IRVINE, Calif., and SANTA ROSA, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq: ELGX) and TriVascular Technologies, Inc. (Nasdaq: TRIV) announced today that they have entered into a definitive merger agreement under which... More